甲状腺癌患者外周血血栓素B2和P-选择素表达与预后的相关性研究

Correlation between the expression of TXB2 and P-selectin in peripheral blood and the prognosis of thyroid cancer

目的探讨甲状腺癌患者外周血血栓素B2(TXB2)和P-选择素(P-selectin)的表达与预后的相关性。方法选取2015年9月至2018年4月间陕西省康复医院收治的128例甲状腺局灶性病变患者,其中48例甲状腺癌患者纳入甲状腺癌组,80例结节性甲状腺肿患者纳入结节组。检测两组患者外周血TXB2和P-selectin表达水平,随访甲状腺癌患者的预后并进行相关性分析。结果甲状腺癌组患者外周血TXB2含量高于结节组,P-selectin含量低于结节组,差异均有统计学意义(均P<0.05)。随访至2019年8月,甲状腺癌组患者总生存时间为(28.29±1.22)个月。单因素直线相关分析显示,甲状腺癌组患者预后总生存时间与TXB2含量成正相关,与P-selectin含量成负相关,差异均有统计学意义(均P<0.05)。多因素分析,淋巴结转移、临床分期、TXB2和P-selectin都为影响患者预后总生存时间的主要因素,差异均有统计学意义(均P<0.05)。结论甲状腺癌患者的预后与外周血TXB2和P-selectin表达有相关性,TXB2和P-selectin为影响甲状腺癌患者预后总生存时间的主要因素。

Objective To investigate the relationship between the expression of thromboxane B2(TXB2)and P-selectin in peripheral blood and the prognosis of thyroid cancer.Methods From September2015 to April 2018,128 patients with focal thyroid lesions were enrolled at Shaanxi Rehabilitation Hospital.Among them,48 patients with thyroid cancer were included in the thyroid cancer group and 80 patients with nodular goiter were included in the nodular group.The expression levels of TXB2 and P-selectin in peripheral blood were detected in the two groups.Patients were followed up for the prognosis and the correlation was analyzed.Results The TXB2 level in peripheral blood was higher in the thyroid cancer group than in the nodule group,and the P-selectin level were lower in the thyroid cancer group than in the nodule group.(all P<0.05).When patients were followed-up until August 2019,the overall survival was 28.29±1.22 months in the thyroid cancer group.Univariate linear correlation analysis showed that the overall survival time were positively correlated with TXB2 content,and were negatively correlated with P-selectin content(all P<0.05).Multivariate analysis showed that lymph node metastasis,clinical stage,TXB2,and P-selectin were the main factors influencing the overall survival(all P<0.05).Conclusion TXB2 and Pselectin are the main factors influencing the overall survival in patients with thyroid cancer.